NGeneBio Co., Ltd. (KOSDAQ:354200)

Market Cap	56.21B
Revenue (ttm)	9.98B +61.7%
Net Income	-12.96B
EPS	-771.98
Shares Out	25.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,109,115
Average Volume	1,199,315
Open	2,015.00
Previous Close	2,015.00
Day's Range	1,959.00 - 2,480.00
52-Week Range	1,325.00 - 2,480.00
Beta	1.04
RSI	76.36
Earnings Date	Mar 20, 2026

About NGeneBio

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 354200

Financial Performance

In 2024, NGeneBio's revenue was 5.69 billion, an increase of 30.80% compared to the previous year's 4.35 billion. Losses were -12.63 billion, -1.11% less than in 2023.